Royalty Pharma
RPRX • NASDAQ
Royalty Pharma is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Pablo Legorreta, with a market cap of $19.7B.
CEOPablo Legorreta
Next Earnings
Upcoming earnings announcement for Royalty Pharma
Date
Thursday, May 7, 2026 (in 2 months)
Timing
Before Market Open (7:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
$1.19
Revenue Estimate
$899.3M
Earnings History
Past 12 earnings reports for Royalty Pharma
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Feb 11, 2026 | Q4 2025 | $1.47Est: $1.33 | +10.5% | $622.0MEst: $832.6M | -25.3% |  10-K |
| Nov 5, 2025 | Q3 2025 | $1.17Est: $1.07 | +9.3% | $609.0MEst: $779.4M | -21.9% | 10-Q |
| Aug 6, 2025 | Q2 2025 | $1.14Est: $1.05 | +8.6% | $579.0MEst: $690.7M | -16.2% | 10-Q |
| May 8, 2025 | Q1 2025 | $1.06Est: $0.95 | +11.3% | $568.0MEst: $724.7M | -21.6% | 10-Q |
| Feb 11, 2025 | Q4 2024 | $1.16Est: $1.05 | +10.5% | $594.0MEst: $743.6M | -20.1% | 10-K |
| Nov 6, 2024 | Q3 2024 | $1.04Est: $0.93 | +11.8% | $565.0MEst: $696.1M | -18.8% | 10-Q |
| Aug 8, 2024 | Q2 2024 | $0.96Est: $0.99 | -3.0% | $537.0MEst: $628.3M | -14.5% | 10-Q |
| May 9, 2024 | Q1 2024 | $0.98Est: $0.99 | -1.0% | $568.0MEst: $663.2M | -14.4% | 10-Q |
| Feb 15, 2024 | Q4 2023 | $1.15Est: $0.99 | +16.2% | $596.0MEst: $673.7M | -11.5% | 10-K |
| Nov 8, 2023 | Q3 2023 | $0.79Est: $0.77 | +2.6% | $536.0MEst: $614.4M | -12.8% | — |
| Aug 8, 2023 | Q2 2023 | $0.84Est: $0.83 | +1.2% | $538.0MEst: $538.5M | -0.1% | 10-Q |
| May 9, 2023 | Q1 2023 | $1.60Est: $1.27 | +26.0% | $684.0MEst: $852.9M | -19.8% | — |